Loading clinical trials...
Loading clinical trials...
A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
Conditions
Interventions
BMS-986299
Nivolumab
+1 more
Locations
9
United States
Local Institution - 0003
La Jolla, California, United States
Local Institution
Orange, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Local Institution
New Haven, Connecticut, United States
Local Institution
Detroit, Michigan, United States
Washington University
St Louis, Missouri, United States
Start Date
April 5, 2018
Primary Completion Date
February 14, 2022
Completion Date
February 14, 2022
Last Updated
May 23, 2022
NCT04657068
NCT04900818
NCT05004116
NCT06440005
NCT07246954
NCT06242470
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions